RYBP stabilizes p53 by modulating MDM2Novel MDM2 p53-independent functions identified through RNA silencing technologiesStructure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymesJKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacologyPhase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implicationsDivergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.Antisense oligonucleotide inhibitors of MDM2 oncogene expression.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapyRecent advances in experimental molecular therapeutics for malignant gliomas.Wnt/beta-catenin signaling pathway as a novel cancer drug target.MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.Oncogenes as novel targets for cancer therapy (part III): transcription factors.Antisense approaches in drug discovery and development.Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.NFAT as cancer target: mission possible?Antisense-based cancer therapeutics: are we there yet?Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapAStabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish.Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of actionAnti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.
P50
Q24309385-FD98C18B-F2E8-492C-9B24-A7BFEFFEA3C0Q28289965-05E7A27A-B794-4CE9-B6C3-ED50D2C1F342Q28473113-5B9E58BD-4030-4306-8EBF-47BDA6D85A6DQ28482983-8447A7EB-EC8C-4675-9CCF-CFF15CF846E0Q28483753-0FB65FA3-557E-4C95-80DC-E7D58C7CC4C3Q33365885-58ABCE04-C207-4DA1-9425-7FE6FF1732FAQ33932866-F47F3DEE-4CBB-449A-8B48-8F98D6100507Q34218811-0E0B692E-77FE-44A2-93A2-342BC9CBF585Q34388038-C242E7B8-5F21-4FEF-97FA-5519DB375E5BQ34435519-F6592F56-C830-4D73-BB09-25C69446CB5DQ34980516-3CD16A67-BE00-40F2-B790-207DA0FEAF95Q35112917-1D05787A-B1A9-4301-BC01-4FD7EBD5E23FQ35550054-F529FD2A-7025-4706-B3D8-5620F364BD8BQ35787329-0A3F7441-DBC0-4F4C-B7C0-94F1E03A106AQ35832111-1DDB39F9-CAAE-4D42-9280-76C230072300Q35849672-53475B90-0821-49EC-8BC3-97924799D85BQ35971885-F6EE73BD-9413-4A47-943F-4FA649289134Q36047902-3AE017A6-81D9-46F6-A3B0-2AEB96606BAAQ36047909-A9164D20-930D-4AC4-940B-2CF2D463ABD8Q36088007-3E9DDC14-4ABB-43D8-8ABE-341E0AF0BBB9Q36161416-CA7D5CF3-D918-4D8B-BDF2-947492D7CE2FQ36216395-7A008DB4-E65A-415A-9766-FAC2EA5AD034Q36217813-D6E67862-5A77-423B-8213-8CFC388925ACQ36230146-6609E08D-F2FC-40FE-9E8A-CA884716FC0AQ36273192-BE2557C2-7534-416F-879D-683E34874AF9Q36304604-7167B745-CA4C-4BCB-B48D-2D54367FBE82Q36334763-42C834BE-1006-4E8E-BB52-D1A4F8A2E0CAQ36455193-A1FA9599-09BA-4F3A-B7AC-01B7E4660B41Q36458427-734EB1E6-71E0-44C9-8CF4-D7CAE2B3B76CQ36545083-5C2394B1-43F1-474D-A449-88DD3624AC1AQ38320884-A16A0851-2569-4116-B7B3-9098EF48B987Q38335349-BEB77032-DC2D-48EA-90BA-8C92FB150F43Q38344527-838E50DE-DE20-4707-8E22-BA46780FE57EQ38345102-189AD558-7885-4149-A762-A750A934CC4EQ39160044-DB6ADE0F-3E30-474D-89D0-69A5856D1279Q39162463-6A420E89-C620-4440-ACA1-E9205E72C386Q39885740-801AF405-1D8E-4938-BBBE-8FF76A057EECQ39897596-0C70A23B-B765-4471-B904-67C788707F92Q40005116-E3E987EE-9813-4ADD-B8FF-ADA13515956DQ40135561-1B359FB7-345F-4764-A933-963FF04AE51C
P50
description
farmacoloog
@nl
name
Ruiwen Zhang
@ast
Ruiwen Zhang
@en
Ruiwen Zhang
@es
Ruiwen Zhang
@nl
type
label
Ruiwen Zhang
@ast
Ruiwen Zhang
@en
Ruiwen Zhang
@es
Ruiwen Zhang
@nl
prefLabel
Ruiwen Zhang
@ast
Ruiwen Zhang
@en
Ruiwen Zhang
@es
Ruiwen Zhang
@nl